Education
About Us
Working with TipRanks
Follow Us
Scientific Industries Inc (SCND)
OTHER OTC:SCND
Top Page
Scientific Industries
(OTC:SCND)
Select Model
Select Model
Rating:41Neutral
Price Target:
$0.57
▼(-5.50% Downside)
The overall stock score is primarily impacted by the company's poor financial performance, characterized by declining revenues and cash flow challenges. Technical analysis indicates a bearish trend, and valuation metrics are unfavorable due to negative profitability and lack of dividends. These factors collectively result in a low stock score.
Positive Factors
Product Innovation
SCND's focus on innovative laboratory equipment like the Vortex-Genie positions it well in the biotech and life sciences sectors, supporting long-term demand.
Strategic Partnerships
Strategic partnerships enhance SCND's distribution capabilities, potentially leading to increased market penetration and sustained revenue growth.
Revenue Model
Direct sales to end-users ensure a stable revenue stream, as SCND caters to essential sectors like pharmaceuticals and education, which have consistent demand.
Negative Factors
Declining Revenue
Declining revenues indicate challenges in market demand or competitive positioning, potentially impacting long-term financial health and growth prospects.
Negative Cash Flow
Negative cash flows suggest operational inefficiencies and may limit SCND's ability to invest in growth opportunities or manage financial obligations.
Profitability Challenges
Decreasing profit margins and net losses reflect operational challenges, which could hinder SCND's ability to achieve sustainable profitability.
Scientific Industries (SCND) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.16M
Dividend YieldN/A
Average Volume (3M)12.23K
Price to Earnings (P/E)―
Beta (1Y)0.79
Revenue Growth-15.84%
EPS Growth77.81%
CountryUS
Employees61
SectorTechnology
Sector Strength88
IndustryHardware, Equipment & Parts
Share Statistics
EPS (TTM)0.34
Shares Outstanding11,928,599
10 Day Avg. Volume13,652
30 Day Avg. Volume12,230
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Scientific Industries Business Overview & Revenue Model
Company DescriptionScientific Industries, Inc. (SCND) is a leading provider of innovative laboratory equipment and solutions, primarily serving the biotechnology, pharmaceutical, and life sciences sectors. The company specializes in the design and manufacture of bioprocessing equipment, including its flagship product, the Vortex-Genie, which is widely recognized for its efficiency in mixing and sample preparation. Additionally, SCND offers a range of laboratory instruments and consumables that enhance research capabilities and streamline workflows for scientific professionals.
How the Company Makes MoneyScientific Industries generates revenue primarily through the sale of its bioprocessing equipment and laboratory instruments. Their revenue model is based on direct sales to end-users, including research institutions, pharmaceutical companies, and educational entities. Key revenue streams include the sale of laboratory mixers, vortex mixers, and other related products, as well as ongoing maintenance and support services for their equipment. The company also benefits from strategic partnerships with distributors who expand its market reach, along with potential licensing agreements for proprietary technologies that enhance their product offerings.
Scientific Industries Earnings Call Summary
Earnings Call Date:Nov 15, 2024
(Q3-2024)
| % Change Since: |
Next Earnings Date:Apr 06, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant growth in the VIVID pill counter business and successful cost-cutting initiatives, alongside promising developments and strategic partnerships in the bioprocessing segment. However, challenges in the European market remain a concern.Q3-2024 Updates
Positive Updates
VIVID Pill Counter Business Growth
VIVID sales in the third quarter were up 50% compared to the second quarter of this year and 12% compared to the same quarter last year. The development of a new VIVID workstation is expected to be a game-changer in the market.
Cost-Cutting Initiatives
The company successfully reduced operating expenses by over $1 million, or roughly 22%, compared to the same time frame last year, and improved cash burn rate without affecting the top line.
Bioprocessing Segment Performance
Sales compared to last year were up 12%, with improved gross margins and lower expenditures, resulting in a 27% improvement in EBITDA. The U.S. team reported a breakeven result with a positive EBITDA margin of 14%.
Strong Pipeline and New Product Development
A 90% increase in the commercial pipeline value was reported, alongside significant advancements in key projects such as the development of PAH technology and the new generation of the liquid injection system.
Strategic Partnerships
Secured partnerships and endorsements from major industry players like Merck, which are expected to positively influence the company's commercial track.
Negative Updates
Challenging Bioprocessing Market
The bioprocessing segment faced a challenging environment with budget constraints impacting customers, particularly in Europe, leading to postponed equipment investments.
Company Guidance
During the third quarter of 2024, Scientific Industries demonstrated significant progress in its strategic transformation into a life sciences tool business with notable growth in sales, margins, and recurring revenue. The legacy Genie business experienced a recovery, generating positive cash flow that supports investments in the VIVID pill counter business, which saw a 50% increase in sales compared to the previous quarter and 12% year-over-year growth. The company is excited about the upcoming launch of the VIVID workstation, a new all-in-one pill counter and pharmacy management system. In the bioprocessing segment, sales increased by 12% compared to the previous year, with a remarkable 61% year-over-year growth in the U.S. market. Efforts to improve cost efficiency resulted in a reduction of operating expenses by over $1 million, or 22%, compared to the previous year. The company also reported a positive EBITDA margin of 14% for its U.S. entity in September, marking a significant milestone. Scientific Industries continues to invest in R&D and commercial activities, with a growing commercial pipeline and the successful launch of the DOTS platform, reflecting its potential to deliver long-term shareholder value.Scientific Industries Financial Statement Overview
Summary
Scientific Industries is facing profitability and cash flow challenges, with declining revenue growth and significant losses impacting margins. Despite a strong equity position and low leverage, the company's operational struggles and liquidity issues pose risks to financial stability.Income Statement
Scientific Industries shows declining revenue growth with a drop in annual revenue from $10,475,600 to $11,111,500, resulting in negative revenue growth. The company has a negative net profit margin and EBIT margin due to significant losses in 2023, indicating profitability challenges. Despite a moderate gross profit margin, overall profitability remains weak.35
Negative
Balance Sheet
The company maintains a strong equity position with a high equity ratio, indicating financial stability. However, the negative net income impacts return on equity. The debt-to-equity ratio remains low, showing minimal leverage, which is a positive aspect of the balance sheet.45
Neutral
Cash Flow
The company faces negative free cash flow growth and significant operating cash flow deficits. The operating cash flow to net income ratio indicates cash flow challenges relative to reported losses, highlighting liquidity issues.30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.95M | 10.71M | 11.11M | 10.48M | 9.78M | 8.57M |
| Gross Profit | 3.71M | 4.73M | 5.10M | 4.64M | 4.98M | 3.85M |
| EBITDA | -662.10K | -5.89M | -8.51M | -7.41M | -4.46M | -979.00K |
| Net Income | -1.24M | -6.45M | -9.09M | -8.15M | -3.11M | -703.30K |
Balance Sheet | ||||||
| Total Assets | 14.56M | 11.56M | 16.73M | 18.07M | 29.01M | 14.80M |
| Cash, Cash Equivalents and Short-Term Investments | 8.29M | 2.57M | 5.72M | 6.20M | 13.42M | 7.89M |
| Total Debt | 820.00K | 1.00M | 1.33M | 0.00 | 1.49M | 1.47M |
| Total Liabilities | 2.10M | 2.44M | 2.85M | 3.28M | 2.78M | 3.08M |
| Stockholders Equity | 12.46M | 9.12M | 13.89M | 14.79M | 26.22M | 11.72M |
Cash Flow | ||||||
| Free Cash Flow | -4.31M | -3.78M | -6.29M | -6.20M | -3.56M | -244.80K |
| Operating Cash Flow | -4.24M | -3.68M | -6.16M | -5.70M | -3.30M | -168.10K |
| Investing Cash Flow | 2.88M | 2.87M | -735.10K | 3.61M | -10.88M | -84.10K |
| Financing Cash Flow | -3.17M | 645.70K | 5.75M | 2.31M | 16.31M | 6.21M |
Scientific Industries Technical Analysis
Negative
0.60
Price Trends
0.64
Negative
0.68
Negative
0.74
Negative
Market Momentum
-0.01
Negative
48.22
Neutral
91.66
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SCND, the sentiment is Negative. The current price of 0.6 is below the 20-day moving average (MA) of 0.60, below the 50-day MA of 0.64, and below the 200-day MA of 0.74, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 48.22 is Neutral, neither overbought nor oversold. The STOCH value of 91.66 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SCND.
Scientific Industries Risk Analysis
Scientific Industries disclosed 12 risk factors in its most recent earnings report. Scientific Industries reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Scientific Industries Peers Comparison
UnderperformOutperform
Sector (61)
SCND
Scientific Industries
0.60
-0.35
-36.84%
ELTK
Eltek
8.76
-2.04
-18.89%
IMTE
Integrated Media Technology
0.64
-0.68
-51.52%
SOBR
SOBR Safe
2.37
-9.73
-80.41%
OST
Ostin Technology Group Co., Ltd.
1.70
-48.30
-96.60%
SVRE
SaverOne 2014 Ltd. ADR
1.40
-124.60
-98.89%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.